Keywords: erbitux, extends, nsclc, survival, up, months, data

Erbitux extends NSCLC survival up to 15 months

Article | 24 November 2008

Print This

Data presented at this year's Chicago Multidisciplinary Symposium in Thoracic Oncology show that patients with non-small cell lung cancer who ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in